VERAXA Biotech (NASDAQ: VRXA) today issued a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company reported that its pipeline now comprises four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.
VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. According to the company, this strategy aims to allocate resources to its most promising next-generation cancer therapies while potentially generating near-term revenue through partnerships.
Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in VERAXA's differentiated BiTAC platform and its potential to secure strategic collaborations. The company said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
The BiTAC platform is designed to engage T cells for tumor killing, while the bispecific ADC programs combine targeting and cytotoxic payload delivery. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.
Additional details are available in the full press release at https://ibn.fm/xTF5q. For the latest news and updates relating to VRXA, visit the company's newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this release involve risks and uncertainties, including those set forth in the Company's filings with the SEC. Undue reliance should not be placed on these statements, and the company undertakes no duty to update them unless required by law.
